RIVASTIGMINE CINFA 9.5 mg/24h TRANSDERMAL PATCHES

2. What you need to know before you start using Rivastigmine Cinfa

Do not use Rivastigmine Cinfa

• if you are allergic to rivastigmine or any of the other ingredients of this medicine (listed in section 6).
• if you have ever had an allergic reaction to a similar medicine (carbamate derivatives).
• if you have a skin reaction that spreads beyond the size of the patch, if there is a more intense local reaction (such as blisters, increasing skin inflammation, swelling), and if there is no improvement within 48 hours after removing the transdermal patch.

If you are in any of these situations, inform your doctor and do not use rivastigmine transdermal patches.

Warnings and precautions

Consult your doctor or pharmacist before starting to use rivastigmine:

• If you have or have ever had any heart problems, such as an irregular or slow heartbeat, prolonged QTc, family history of prolonged QTc, torsades de pointes, or if you have low levels of potassium or magnesium in your blood.
• If you have or have ever had an active stomach ulcer.
• If you have or have ever had difficulty urinating.
• If you have or have ever had seizures.
• If you have or have ever had asthma or a severe respiratory disease.
• If you suffer from tremors.
• If you have a low body weight.
• If you have gastrointestinal reactions such as a feeling of nausea, vomiting, and diarrhea. You may become dehydrated (lose a large amount of fluid) if vomiting or diarrhea is prolonged.
• If you have liver problems (liver failure).

If you are in any of these situations, your doctor may consider it necessary to monitor you more closely while you are being treated.

If you have not used the patches for more than three days, do not put on another one without consulting your doctor first.

Children and adolescents

This medicine must not be used in the pediatric population for the treatment of Alzheimer's disease.

Other medicines and Rivastigmine Cinfa

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.

Rivastigmine may interfere with anticholinergic medicines, some of which are medicines used to relieve stomach cramps or spasms (e.g., dicyclomine), for the treatment of Parkinson's disease (e.g., amantadine), or to prevent motion sickness (e.g., diphenhydramine, scopolamine, or meclizine).

This medicine must not be administered at the same time as metoclopramide (a medicine used to relieve or prevent nausea and vomiting). Taking the two medicines together may cause problems such as stiffness in the limbs and hand tremors.

If you are going to have surgery while using rivastigmine transdermal patches, inform your doctor that you are using it, as it may potentiate the effects of some muscle relaxants used in anesthesia.

Caution should be exercised when using this medicine with beta-blockers (medicines such as atenolol used to treat high blood pressure, angina, and other heart conditions). Taking the two medicines together may cause complications such as a decrease in heart rate (bradycardia) that can lead to fainting or loss of consciousness.

Caution should be exercised when using rivastigmine with other medicines that may affect heart rate or the heart's electrical system (QT prolongation).

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.

If you are pregnant, it is necessary to evaluate the benefits of using rivastigmine against the possible adverse effects for the fetus. Rivastigmine should not be used during pregnancy unless clearly necessary.

You should not breastfeed while being treated with this medicine.

Driving and using machines

Your illness may affect your ability to drive or use machines, and you should not carry out these activities unless your doctor tells you it is safe to do so. Rivastigmine may cause dizziness and somnolence, mainly at the start of treatment or when increasing the dose. If you experience these effects, do not drive or use machines.

3. How to use Rivastigmine Cinfa

Follow exactly the instructions for administration of this medicine given by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.

IMPORTANT:

• Remove the previous patch before applying a NEW patch.
• ONLY ONE patch per day.
• Do NOT cut the patch into pieces.
• Press the patch firmly against the skin with the palm of your hand for at least 30 seconds.

How to start treatment

Your doctor will tell you which dose of rivastigmine transdermal patches is most suitable for you.

• Normally, treatment is started with rivastigmine 4.6 mg/24 h.
• The recommended daily dose is rivastigmine 9.5 mg/24 h. If this dose is well tolerated, the doctor treating you may consider increasing the dose to 13.3 mg/24 h.
• Wear only one rivastigmine patch at a time and replace the patch with a new one after 24 hours.

During treatment, your doctor may adjust the dose depending on your individual needs.

If you have not used the patches for more than three days, do not put on another one without consulting your doctor first. Treatment with the transdermal patch can be restarted at the same dose if treatment is not interrupted for more than three days. Otherwise, your doctor will have you restart your treatment with rivastigmine 4.6 mg/24 h.

Rivastigmine can be used with food, drinks, and alcohol.

Where to apply your Rivastigmine Cinfa transdermal patch

• Before applying a patch, make sure the skin is clean, dry, and hairless, without powders, oils, moisturizers, or lotions that may prevent the patch from sticking well to the skin, without cuts, redness, or irritations.
• Remove carefully any patch you are already wearing before applying a new one.Wearing multiple patches on your body could expose you to an excessive amount of this medicine, which could be potentially dangerous.
• Apply ONLY ONEpatch per day to ONLY ONEof the possible areas as shown in the following diagrams:
• • upper left orupper right arm
  • upper left orupper right chest (avoiding the breasts in women)
  • upper left orupper right back
  • lower left or lower right back

Every 24 hours, remove the previous patch before applying a NEW patch to ONLY ONE of the following possible areas

Each time you change the patch, you must remove the previous day's patch before applying a new patch to a different area of skin (e.g., one day on the right side of the body and the next day on the left side; or one day on the upper part of the body and the next day on the lower part). Wait at least 14 days before applying a new patch to exactly the same area of skin.

How to apply your Rivastigmine Cinfa transdermal patches

The rivastigmine patches are thin, opaque plastic and stick to the skin. Each patch is in a pouch that protects it until you are ready to apply it. Do not open the pouch or remove the patch until you are ready to apply it.

Carefully remove any existing patch before applying a new one.

Patients who are starting treatment for the first time and patients who are restarting treatment with rivastigmine after an interruption of treatment must start with the second figure.

• Each patch is in an individual protective pouch. Only open the pouch when you are ready to apply the patch. Cut the pouch along the dotted line with scissors and remove the patch from the pouch.

• A divided protective liner covers the adhesive side of the patch. Remove the first sheet of the liner without touching the adhesive side of the patch with your fingers.

• Place the adhesive side of the patch on the upper or lower back or on the upper arm or chest (avoiding the breasts in women)and then remove the second sheet of the protective liner.

• Press the patch firmly against the skin with the palm of your hand for at least 30 seconds and make sure the edges are well stuck.

• If it helps, you can write on the patch, for example, the day of the week, with a fine-tipped pen.

You must wear the patch continuously until it is time to change it for a new one. When you apply a new patch, you can try different areas to find the ones that are most comfortable for you and where clothing does not rub against the patch.

How to remove your Rivastigmine Cinfa transdermal patch

Gently pull on one of the edges of the patch to slowly peel it off the skin. If adhesive residues remain on the skin, soak the area with warm water and mild soap or use baby oil to remove it. Do not use alcohol or other solvents (nail polish removers or other solvents).

After removing the patch, wash your hands with soap and water. If you get the patch in your eyes or if your eyes become red after handling the patch, rinse immediately with plenty of water and seek medical advice if the symptoms do not resolve.

Can you wear your Rivastigmine Cinfa transdermal patch when bathing, swimming, or exposing yourself to the sun?

• Bathing, swimming, or showering should not affect the patch. Make sure it does not peel off partially while you perform these activities.
• Do not expose the patch to an external heat source (e.g., excessive sunlight, sauna, sunbed) for long periods.

What to do if a patch falls off

If a patch falls off, apply a new one for the rest of that day and change it the next day at the usual time.

When and for how long should you wear your Rivastigmine Cinfa transdermal patches

• To benefit from your treatment, you must apply a new patch every day, preferably at the same time.
• Wear only one Rivastigmine Cinfa patch at a time and replace the patch with a new one after 24 hours.

If you use more Rivastigmine Cinfa than you should

If you accidentally apply more than one patch, remove all patches from the skin and inform your doctor. You may need medical attention. Some people who have accidentally taken too much rivastigmine orally have had nausea, vomiting, diarrhea, high blood pressure, and hallucinations. There may also be a slowing of the heart rate and fainting.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medicine and the amount ingested.

If you forget to use Rivastigmine Cinfa

If you realize you have forgotten to apply a patch, apply it immediately. The next day, apply the next patch at the usual time. Do not apply two patches to make up for the one you forgot.

If you stop using Rivastigmine Cinfa

Tell your doctor or pharmacist if you stop using the patches.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible Adverse Effects

Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.

You may have adverse effects more frequently when starting your treatment or when your dose is increased. Generally, the adverse effects will slowly disappear as your body gets used to the medicine.

If you notice any of the following adverse effects that may be serious, remove the patch and inform your doctor immediately.

Frequent(may affect up to 1 in 10 people)

• Lack of appetite
• Dizzy sensation
• Feeling of agitation or numbness
• Urinary incontinence (inability to stop urine properly).

Infrequent(may affect up to 1 in 100 people)

• Heart rhythm problems such as slow heart rate
• Seeing things that do not really exist (hallucinations)
• Stomach ulcer
• Dehydration (loss of a large amount of fluid)
• Hyperactivity (high level of activity, restlessness)
• Aggressiveness

Rare(may affect up to 1 in 1,000 people)

• Falls

Very Rare(may affect up to 1 in 10,000 people)

• Stiffness of the arms and legs
• Tremor in the hands

Frequency Not Known(cannot be estimated from the available data)

• Allergic reaction where the patch was applied, such as blisters or skin inflammation
• Worsening of Parkinson's disease signs – such as tremor, stiffness, and difficulty moving
• Pancreatitis – signs include pain in the upper part of the stomach, often accompanied by a feeling of dizziness (nausea) or dizziness (vomiting)
• Fast or irregular heart rate
• High blood pressure
• Epileptic seizures (convulsions)
• Liver disorders (yellowing of the skin, yellowing of the whites of the eyes, abnormal darkening of urine or unexplained nausea, vomiting, fatigue, and loss of appetite)
• Changes in analyzes that show liver function
• Feeling of restlessness
• Nightmares

If you notice any of the adverse effects listed above, remove the patch and inform your doctor immediately.

Other Adverse Effects Experienced with Rivastigmine Capsules or Oral Solution and That May Occur with Patches:

Frequent(may affect up to 1 in 10 people)

• Excessive saliva
• Lack of appetite
• Feeling of agitation
• Feeling of general discomfort
• Tremor or feeling of confusion
• Increased sweating

Infrequent(may affect up to 1 in 100 people)

• Irregular heart rate (e.g., fast heart rate)
• Difficulty sleeping
• Accidental falls

Rare(may affect up to 1 in 1,000 people)

• Epileptic seizures (convulsions)
• Ulcer in the intestine
• Chest pain – probably caused by spasm in the heart

Very Rare(may affect up to 1 in 10,000 people)

• High blood pressure
• Pancreatitis – signs include severe pain in the upper part of the stomach, often with a feeling of dizziness (nausea) or dizziness (vomiting)
• Gastrointestinal bleeding – manifested as blood in the stool or when vomiting
• Seeing things that do not exist (hallucinations)
• Some people who have been intensely dizzy (vomiting) have had a tear in part of the digestive tube that connects their mouth to their stomach (esophagus)

Frequency Not Known(cannot be estimated from the available data)

• Pisa syndrome (a condition that involves involuntary muscle contraction and abnormal tilting of the body and head to one side)

Patients with Dementia or Parkinson's Disease

These patients experience some adverse effects more frequently and also have some additional adverse effects:

Frequency Not Known(cannot be estimated from the available data)

• Pisa syndrome (a condition that involves involuntary muscle contraction and abnormal tilting of the body and head to one side)

Reporting of Adverse Effects

If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.

5. Conservation of Rivastigmine Cinfa

Keep this medicine out of sight and reach of children.

Do not use this medicine after the expiration date that appears on the box and on the envelope after CAD. The expiration date is the last day of the month indicated.

Do not use any patch if you observe that it is damaged or shows signs of tampering.

Keep it in the original packaging to protect it from light.

Keep the transdermal patch in the envelope until use.

After removing a patch, fold it in half with the adhesive side facing in and press. After introducing it into the original envelope, when disposing of the patch, make sure it is out of sight and reach of children. After removing the patch, do not touch your eyes, and wash your hands well with water and soap.

Medicines should not be thrown down the drain or into the trash. Deposit the packaging and medicines that you no longer need in the SIGRE Point of the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines that you no longer need. This way, you will help protect the environment.

6. Package Contents and Additional Information

Composition of Rivastigmine Cinfa

• The active ingredient is rivastigmine. Each patch contains 18 mg of rivastigmine in 10 cm2 and releases 9.5 mg of rivastigmine in 24 hours.

• The other components are: polyester film, silicone-coated polyester film, fluorinated polyester film, acrylic adhesive (Duro-Tak 87-235A), acrylate copolymer (Plastoid B), ethyl acetate, silicone adhesive (Bio-PSA 7-4302), and ink.

Appearance of the Product and Package Contents

Rivastigmine Cinfa 9.5 mg/24 h transdermal patches are presented in the form of a transdermal patch composed of a rounded adhesive and a rectangular support film. Each envelope contains a transdermal patch.

Rivastigmine Cinfa 9.5 mg/24 h transdermal patches are available in packages containing 60 envelopes.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder

Laboratorios Cinfa, S.A.

Carretera Olaz-Chipi, 10. Polígono Industrial Areta

31620 Huarte (Navarra) - Spain

Manufacturer

Laboratorios Cinfa, S.A.

Carretera Olaz-Chipi, 10. Polígono Industrial Areta

31620 Huarte (Navarra) – Spain

or

Eurofins PHAST GmbH

Kardinal-Wendel-Strasse 16,

66424 Homburg, Germany

or

ACC GmbH Analytical Clinical Concepts

Schöntalweg 9,

63849 Leidersbach, Germany

Date of the Last Revision of this Prospectus:December 2024

Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.

You can access detailed and updated information about this medicine by scanning the QR code included in the prospectus and packaging with your mobile phone (smartphone). You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/80659/P_80659.html

QR code to: https://cima.aemps.es/cima/dochtml/p/80659/P_80659.html